Logo
x

Search

Subscribe Now

Positive

ViiV Healthcare Presents Results of GSK3640254 (GSK'254) in P-IIa study for the Treatment of HIV at CROI

ViiV Healthcare Presents Results of GSK3640254 (GSK'254) in P-IIa study for the Treatment of HIV at CROI

  • March 10, 2021
Novo Nordisk Receives the CHMP's Positive Opinion for Sogroya (somapacitan)

Novo Nordisk Receives the CHMP's Positive Opinion for Sogroya (somapacitan)

  • February 1, 2021
Incyte Receive Positive CHMP's Opinion for Pemigatinib

Incyte Receive Positive CHMP's Opinion for Pemigatinib

  • February 1, 2021
Novartis's Entresto Receives the US FDA's Advisory Committee Recommendation to Treat Patients with HFpEF

Novartis's Entresto Receives the US FDA's Advisory Committee Recommendation to Treat Patients with HFpEF

  • December 17, 2020
Daiichi Sankyo and AZ's Trastuzumab Deruxtecan Receives CHMP's Recommendation for Approval to Treat HER2 Positive Metastatic Breast Cancer

Daiichi Sankyo and AZ's Trastuzumab Deruxtecan Receives CHMP's Recommendation for Approval to Treat HER2 Positive Metastatic Breas...

  • December 14, 2020
Pfizer Reports Results of Abrocitinib in Fifth P-lll JADE REGIMEN Across Different Dosing Regimens

Pfizer Reports Results of Abrocitinib in Fifth P-lll JADE REGIMEN Across Different Dosing Regimens

  • November 12, 2020
EMA Marketing Authorization of New Drugs in October 2024

    EMA Marketing Authorization of New Drugs in October 2024

    • November 21, 2024
    Jazz Pharmaceuticals’ Ziihera (Zanidatamab-hrii) Secures the US FDA’s Accelerated Approval to Treat HER2-Positive (IHC 3+) Biliary Tract Cancer (BTC)

      Jazz Pharmaceuticals’ Ziihera (Zanidatamab-hrii) Secures the US FDA’s Accelerated Approval to Treat HER2-Positive (IHC 3+) Biliary...

      • November 21, 2024
      The US FDA Approves Novartis’ Scemblix for Newly Diagnosed Ph+ CML in Chronic Phase

        The US FDA Approves Novartis’ Scemblix for Newly Diagnosed Ph+ CML in Chronic Phase

        • October 30, 2024
        Dong-A ST Receives the CHMP’s Positive Opinion for Imuldosa (Biosimilar, Stelara)

          Dong-A ST Receives the CHMP’s Positive Opinion for Imuldosa (Biosimilar, Stelara)

          • October 22, 2024
          BeiGene Reports the CHMP’s Positive Opinions for Tevimbra as a 1L Treatment of G/GEJ Cancer and Esophageal Squamous Cell Carcinoma

            BeiGene Reports the CHMP’s Positive Opinions for Tevimbra as a 1L Treatment of G/GEJ Cancer and Esophageal Squamous Cell Carcinoma

            • October 22, 2024
            AstraZeneca and Ionis’ Wainzua (Eplontersen) Receives the CHMP’s Positive Opinion to Treat Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

              AstraZeneca and Ionis’ Wainzua (Eplontersen) Receives the CHMP’s Positive Opinion to Treat Hereditary Transthyretin-Mediated Amylo...

              • October 21, 2024
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.